Zimmer Biomet Holdings, Inc.

ZBH: NYSE
54Total

Lowest reading is at 28 out of 100. All scores are out of 100.

About The Company

CEO

Mr. Ivan Tornos

Market Cap

17.36 Billion USD

Sector

Healthcare

Website

https://www.zimmerbiomet.com

Last Update

28/09/2026, 03:49:00

Description

Zimmer Biomet Holdings, Inc.

Read More

Strongest readings

  • ✔Debt is low at 0.59 times equity
  • ✔Share count has been falling at 0.89% per year

Weakest readings

  • ✘Earnings and cashflow growth is weak (growth score 28 out of 100)
  • ✘The current price sits above estimated fair value (margin of safety -16.79%)
  • ✘Price-to-earnings of 22.1 is above the market average of 19.6

Key Figures

StatusMetricValueReadingMarket avg
✘
Price / earnings (TTM)
22.08x
19.60x
✘
Margin of safety (DCF)
-16.79%
17.95%
✘
Revenue growth (5y average)
6.55%
10.97%
✘
Dividend yield (TTM)
1.08%
1.85%
✔
Share count, per year
-0.89%
0.00%
✘Return on capital employed5.48%
10.00%

The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

Valuation

79 / 100

Priced at or below the market on most measures.

StatusMetricValueReadingMarket avg
✘
Price / earnings
22.08x
19.60x
✔Free cashflow yield8.77%
4.70%
Price / earnings growthN/A1.50x
Price / book1.37x
—
✘
Margin of safety
-16.79%
17.95%

The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

  • ✘Estimated intrinsic value of 75.75 USD is below the current price of 91.04 USD

Desired Margin Of Safety

0%

▼

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Estimated Fair Value: 145.7 USD ✔

Current Price: 91 USD

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated fair value for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel for the impact this has on longterm investment returns and find a margin of safety you are comfortable with.

Growth

28 / 100

Growing more slowly than the market on most measures.

StatusMetricValueReadingMarket avg
✘
Revenue growth
6.55%
10.97%
✘Earnings growth-14.68%
14.48%
✘Cashflow growth10.46%
12.35%

The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

  • ✔Revenue growth has improved this year (8.62% against a five year average of 6.55%)
  • ✔Earnings growth has improved this year (0.61% against a five year average of -14.68%)
  • ✘Free cashflow growth has slowed this year

Health

50 / 100

Balance sheet covers its obligations.

Measured on Leverage and capital, Funding and liquidity, Earnings quality.

StatusMetricValueReadingThreshold
✘Altman-Z score2.36
3.00
✔Piotroski score5.00
5.00
✔Debt / equity0.59x
0.80x
✔Current ratio1.98x
1.00x
✔Interest coverage3.84x
2.50x
✔Free cashflow / debt0.20x
0.15x
✔Debt / capital0.37x
1.00x

The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

    Dividend

    57 / 100

    Covered, with limited headroom.

    StatusMetricValueReadingMarket avg
    ✘
    Dividend yield
    1.08%
    1.85%
    ✘Dividend growth-2.91%
    0.00%
    ✔Payout ratio (earnings)23.35%
    40.00%
    ✔Payout ratio (cashflow)12.37%
    65.00%
    ✔Worst year, last 5 years-0.41%
    -2.00%

    The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

    • ✘Dividend growth has been slowing recently

    Management

    59 / 100

    Returns on capital are at or above the market.

    StatusMetricValueReadingMarket avg
    ✘Return on equity5.55%
    15.00%
    ✘Return on capital employed5.48%
    10.00%
    Return on assets3.05%
    —
    Free cashflow return on capital7.18%
    —
    ✔Return on capital, 5y change3.71%
    0.00%
    ✔
    Share count, per year
    -0.89%
    0.00%
    ✔Share count, recent-3.67%
    0.00%
    ✘Realized buyback return-51.41%
    0.00%
    ✘Goodwill erosion / equity3.17%
    2.00%
    Price volatility, 5 year26.09%
    —

    The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

    • ✔Shares were repurchased while the value score was 79 out of 100
    • ✔Dividends were reduced when earnings fell (dividend -1.29% per year, earnings -14.68% per year)

    Analysts

    not enough data
    StatusMetricValueReadingNeutral
    Analyst opinion scoreN/A50

    The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

    Financial History

    Annual figures across the full reporting history we hold.

    Market Peers

    ZBH

    SEC Filings

    Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

    See 35+ Years Annual Reports

    Other Information

    Company Name

    Zimmer Biomet Holdings, Inc.

    Currency

    USD

    Beta

    0.471

    Vol Avg

    2222646

    Ceo

    Mr. Ivan Tornos

    Cik

    0001136869

    Cusip

    Exchange

    NYSE

    Full Time Employees

    17000

    Industry

    Medical Devices

    Sector

    Healthcare

    Ipo Date

    Address

    345 East Main Street

    City

    Warsaw

    State

    IN

    Country

    United States

    Zip

    46580

    Phone

    574 373 3333

    Analysis Last Updated

    28/09/2026, 03:49:00

    Financial data compiled from SEC EDGAR filings and Yahoo Finance.

    Noticed an error with something on our site?

    Data, not advice. Do your own diligence.

    We Use Cookies